PRESS RELEASE

12 FEBRUARY 2018 | FOR IMMEDIATE RELEASE

Identified: A Host Protein Involved in Enterovirus 71 Infection of the brain in Hand, Foot and Mouth Disease

Singapore, 12 February 2018 — Infection with enterovirus 71 (EV71) causes hand, foot and mouth disease, a highly contagious disease that usually affects children younger than five years of age.¹

In most cases, the disease manifests in a relatively mild manner, as fever, skin rashes and mouth ulcers. However, in a small proportion of patients, the virus infects the brain and can potentially cause fatal conditions such as pulmonary edema (a condition that sees fluid building up in the lungs) and brainstem encephalitis (inflammation of the brain). If the patients survive the infection, they may still experience longer term effects, including cognitive impairment.

The mechanisms by which EV71 infects and replicates in the brain are not well known and have been the subject of active research. Now, a study published in the prestigious microbiology journal *PLOS Pathogens* is the first to identify a host protein, prohibitin (PHB) that is used by EV71 to attack and infect the brain.

The authors, led by Associate Professor Sylvie Alonso from the Department of Microbiology and Immunology at the NUS Yong Loo Lin School of Medicine, focused on PHB out of a panel of proteins that were identified as playing roles during EV71 infection of neuronal cells. PHB, which is found both on the surface of and inside our cells, is involved in many cellular processes and has been implicated in cancer development in other research initiatives. Using a variety of experimental approaches, the team demonstrated that PHB is being used by the virus not only to invade the neuronal cells, but also to multiply inside them.

Additionally, the researchers also showed that a cancer drug (Rocaglamide A) known to inhibit PHB could also be employed to curb EV71 infection in neuronal cells, and thus protect the brain.

This discovery represents the first report of a host protein that is specifically involved in EV71 infection of the brain and could pave the way for the development of specific treatments for serious neurological complications arising from Hand, Foot and Mouth Disease.

Said A/Prof Alonso, “The identification of this protein opens up the possibility now to focus on drug development, since we have shown that targeting this protein allows us to fight the virus. We hope that as we accumulate more and more knowledge on this virus,
pharmaceutical companies will decide to include EV71 in their R&D portfolio to support the research efforts led by academic institutions”.

Added A/Prof Lee Yung Seng, Head of Paediatrics at the National University Hospital, “Essentially, the team has found the protein which allows the virus to get to the brain and cause complications. This protein represents a target for the development of specific treatments that are aimed at preventing this.”

Reference

For media enquiries, please contact:

Justine LAI
Assistant Manager
Dean’s Office, Corporate Communications
NUS Yong Loo Lin School of Medicine
DID: (65) 6772 3831
Mobile: (65) 9738 0669
Email: justine_lai@nus.edu.sg
About the National University of Singapore (NUS)

A leading global university centred in Asia, the National University of Singapore (NUS) is Singapore’s flagship university, which offers a global approach to education and research, with a focus on Asian perspectives and expertise.

NUS has 17 faculties and schools across three campuses. Its transformative education includes a broad-based curriculum underscored by multidisciplinary courses and cross-faculty enrichment. Over 38,000 students from 100 countries enrich the community with their diverse social and cultural perspectives. NUS also strives to create a supportive and innovative environment to promote creative enterprise within its community.

NUS takes an integrated and multidisciplinary approach to research, working with partners from industry, government and academia, to address crucial and complex issues relevant to Asia and the world. Researchers in NUS’ Schools and Faculties, 30 university-level research institutes and centres, and Research Centres of Excellence cover a wide range of themes including: energy, environmental and urban sustainability; treatment and prevention of diseases common among Asians; active ageing; advanced materials; risk management and resilience of financial systems. The University’s latest research focus is to use data science, operations research and cybersecurity to support Singapore’s Smart Nation initiative.

For more information on NUS, please visit www.nus.edu.sg.

About the NUS Yong Loo Lin School of Medicine (NUS Medicine)

Established in 1905, the NUS Yong Loo Lin School of Medicine is the first institution of higher learning in Singapore and the genesis of the National University of Singapore.

The School offers one of the finest undergraduate medical programmes in the Asia Pacific region and enjoys international recognition and respect. The Times Higher Education World University Rankings 2016 by subject and Quacquarelli Symonds (QS) World University Rankings by Subject 2017 list NUS Medicine as a leading medical school in Asia.

It admits 300 students to the MBBS degree programme annually and its principal missions are to educate and train the next generation of healthcare professionals, and foster research that will help to advance the practice of medicine.

The 18 NUS Medicine departments in the basic sciences and clinical specialties work closely with the Centre for Medical Education, the Centre for Biomedical Ethics, the Centre for Healthcare Simulation as well as the restructured public hospitals to ensure that teaching and research are aligned and relevant to Singapore’s healthcare needs. The School is a founding institutional member of the National University Health System.

For more information about NUS Medicine, please visit http://nusmedicine.nus.edu.sg